Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 13/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10944659 | 0.82 | AR (0.43) | ARHTR2AHTR2CHTR2BTRPV4 | |
| SCHEMBL29840280 | 0.81 | AR (0.37) | AR | |
| SCHEMBL3838194 | 0.80 | TRPV4 (0.39) | ARTRPV4CYP11B2CYP11B1 | |
| SCHEMBL31542127 | 0.78 | TRPV4 (0.42) | ARHTR2AHTR2CHTR2BTRPV4 | |
| SCHEMBL3333071 | 0.78 | CYP11B2 (0.42) | ARHTR2AHTR2CHTR2BTRPV4 | |
| SCHEMBL8664256 | 0.78 | TRPV4 (0.42) | ARHTR2AHTR2CHTR2BTRPV4 | |
| SCHEMBL4478973 | 0.75 | CYP11B2 (0.40) | ARHTR2AHTR2CHTR2BTRPV4 | |
| SCHEMBL13199474 | 0.75 | AR (0.45) | ARHTR2AHTR2CHTR2B | |
| SCHEMBL974487 | 0.75 | AR (0.49) | AR | |
| SCHEMBL20517275 | 0.75 | HTR2A (0.37) | ARHTR2AHTR2CHTR2BTRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117024411-B | Isoquinoline as HPK1 inhibitor | 豪夫迈·罗氏有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20260115297-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | ICAHN SCHOOL MED MOUNT SINAI (US) | 2026-04-30 | — | — | US | disclosed |
| EP-3826722-B1 | ISOQUINOLINE COMPOUNDS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2026-02-18 | — | — | EP | disclosed |
| US-12473301-B2 | Isoquinoline compounds for the treatment of cancer | GENENTECH, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-12465648-B2 | Heterobifunctional compounds as degraders of HPK1 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4051680-B1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-12391697-B2 | Condensed bi-heterocycles as inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-12378249-B2 | Isoquinoline compounds and uses thereof | GENENTECH, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-3860995-B1 | ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2025-04-16 | — | — | EP | disclosed |
| EP-4524137-A2 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | Icahn School of Medicine at Mount Sinai (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-2194045-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2010-06-09 | — | — | EP | disclosed |
| EP-2176220-A2 | PYRROLIDIN-2-ONE DERIVATIVES AS ANDROGEN RECEPTOR MODULATOR | Takeda Pharmaceutical Company Limited (JP) | 2010-04-21 | — | — | EP | disclosed |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| WO-2009020234-A2 | PYRROLIDIN-2 -ONE DERIVATIVES AS ANDROGEN RECEPTOR MODULATOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-12 | — | — | WO | disclosed |
| WO-2009020234-A2 | PYRROLIDIN-2 -ONE DERIVATIVES AS ANDROGEN RECEPTOR MODULATOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-12 | — | — | WO | disclosed |
| US-20090042967-A1 | Cyclic amine compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-12 | — | — | US | disclosed |
| US-20090042967-A1 | Cyclic amine compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-12 | — | — | US | disclosed |
| US-20090042967-A1 | Cyclic amine compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378249-B2 | Isoquinoline compounds and uses thereof | HIPK1, HPGDS, IP6K1 | AR 4768/4885HTR2A 3750/4885HTR2C 3466/4885 |
| US-12473301-B2 | Isoquinoline compounds for the treatment of cancer | PGK1, PHKG1, NEK1 | AR 4638/4885HTR2A 3776/4885HTR2C 3167/4885 |
| US-12465648-B2 | Heterobifunctional compounds as degraders of HPK1 | HIPK1, MCL1, HYPK | AR 3877/4885HTR2A 3174/4885HTR2C 3401/4885 |
| US-20260115297-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | TTK, ITK, CLK1 | AR 3687/4885HTR2A 1344/4885HTR2C 1114/4885 |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | AR, NR5A1, NR3C2 | AR 1/4885HTR2A 922/4885HTR2C 400/4885 |
| US-20090042967-A1 | Cyclic amine compounds | SHBG, FSHR, ACP3 | AR 4/4885HTR2A 909/4885HTR2C 2014/4885 |
| US-12391697-B2 | Condensed bi-heterocycles as inhibiting agents for Bruton's tyrosine kinase | ABL1, CDK1, CDK2 | AR 3751/4885HTR2A 2342/4885HTR2C 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.